Alcohol formula

Clearmind Medicine Announces Successful Preclinical Results in MEAI Treatment of Alcohol Use

The preclinical trial demonstrated a high safety profile in addition to a significant suppressive effect on alcohol consumption

VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. CMNDCMNDFJCM)) (“clear mind” or the “Cbusiness“, a biotechnology company focused on the discovery and development of novel therapies derived from psychedelics, today announced positive safety results for its proprietary molecule, MEAI, to treat alcohol abuse.

To assess the efficacy and safety of its psychedelic-derived treatment, Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks. The groups were then given varying daily doses of the new treatment, with intermittent access to alcohol and water. After two weeks, the researchers saw a significant reduction in alcohol consumption in the mice receiving the treatment. The control group showed no statistically significant reduction.

Today’s safety results build on these positive efficacy results and mark an important milestone as Clearmind plans to conduct FDA-regulated clinical trials with humans later this year.

“We are extremely pleased with the success of our preclinical trials to date, which have now demonstrated both safety and efficacy in reducing alcohol consumption,” said Dr. Adi Zuloff-Shani, CEO by Clearmind. “We believe our novel, psychedelic- has the potential to help millions of people around the world suffering from alcohol abuse, as well as a range of other mental health issues. We look forward to our progress continuous.

In accordance with the behavioral paradigm and to assess safety, histopathological tests were performed on selected organs (heart, lungs, liver, kidneys, brain, pancreas, spleen and thyroid gland) of the test animals to determine possible toxicological effects of the MEAI. No treatment-related histological changes were observed among all MEAI treatment groups compared to naïve and vehicle control animals in all organs examined.

About Clearmind Medicine

Clear Mind Medicine is a new biotechnology company focused on the discovery and development of novel psychedelic-derived therapies to address widespread and underserved health conditions, including alcohol use disorders, binge eating and depression.

The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind’s shares are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, on the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF”.

For more information, please contact:
Investor Relations,
Email: [email protected]
Phone: (604) 260-1566
General Information,
[email protected]


This press release may contain forward-looking statements and information based on current expectations. These statements should not be construed as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those implied by such statements. These representations include the timely submission of relevant documentation to the satisfaction of the relevant regulatory authorities and the raising of sufficient funding to carry out the Company’s business strategy. There is no certainty that any of these events will occur. Although these statements are based on management’s reasonable assumptions, there can be no assurance that these assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing in early-stage companies inherently involves a high degree of risk, and an investment in securities of the Company should be considered highly speculative.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of the securities in any province where such offer, solicitation or sale would be unlawful. The securities issued or to be issued under the Private Placement have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States in the United States. lack of registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

main logo